{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid =
| image = Varespladib.svg
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 172732-68-2
| CAS_supplemental  =
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2Q3P98DATH
| PubChem = 155815
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 148674
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 137248
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08107
| C=21|H=20|N=2|O=5
| molecular_weight = 380.4 g/mol
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category = —
| legal_status = investigational
| smiles = CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C21H20N2O5/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = BHLXTPHDSZUFHR-UHFFFAOYSA-N
}}

'''Varespladib''' is an [[enzyme inhibitor|inhibitor]] of the IIa, V, and X [[isoforms]] of [[phospholipase A2#Secreted phospholipases A2 (sPLA2)|secretory phospholipase A2]] (sPLA2).<ref>{{cite press release|publisher=Anthera Pharmaceuticals, Inc.|title=Following Encouraging Results, Anthera to Continue IMACTS Trial for the Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease.|date=24 March 2009|url=http://investor.anthera.com/releasedetail.cfm?ReleaseID=423159
}}</ref><ref name="vm">{{cite web|title=A-002: Short Term (16 week) Treatment of Acute Coronary Syndrome.|publisher=Anthera Pharmaceuticals.|accessdate=6 September 2011|url=http://www.anthera.com/products_a002.asp
}}</ref><ref>{{cite journal|title=Varespladib|journal=American Journal of Cardiovascular Drugs|date=April 2011|volume=11|issue=2|pages=137–43|pmid=21446779|doi=10.2165/11533650-000000000-00000| url= http://adisonline.com/cardiovascular/Abstract/2011/11020/Varespladib.7.aspx
}}</ref> The [[molecule]] acts as an anti-inflammatory agent by disrupting the first step of the [[arachidonic acid pathway]] of [[inflammation]].<ref>{{cite book|vauthors=Baynes JW, Dominiczak MH |year=2005|title=Medical Biochemistry|edition=2|publisher=Elsevier Mosby|pages=555|isbn=0-7234-3341-0
}}</ref> From 2006 to 2012, varespladib was under active investigation by [[Anthera Pharmaceuticals]] as a potential therapy for several [[inflammatory diseases]], including [[acute coronary syndrome]] and [[acute chest syndrome]].<ref name="pr">{{cite press release|publisher=Anthera Pharmaceuticals, Inc.|title=Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.|date=6 September 2006|url=http://investor.anthera.com/releasedetail.cfm?ReleaseID=424037
}}</ref><ref>{{cite web|title=Science: sPLA2|publisher=Anthera Pharmaceuticals|accessdate=6 August 2011|url=http://www.anthera.com/science_spla2.asp
}}</ref> The trial was halted in March 2012 due to inadequate efficacy.<ref>{{cite web|author=ClinicalTrials.gov|url= http://clinicaltrials.gov/ct2/show/NCT01130246|title = VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome.|publisher=United States National Institute of Health|accessdate=2011-08-17}}</ref>

==Oral varespladib==
{{main|varespladib methyl}}

==Intravenous varespladib==
{{drugbox
| drug_name = Varespladib sodium
| verifiedrevid =
| image = Varespladib sodium.svg
| synonyms = A-001
| CAS_number = 172733-42-5
| CAS_supplemental  =
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| PubChem = 23674730
| DrugBank =
| ChemSpiderID = 137249
| ChEMBL = 2107809
| UNII = F6M52CDT0W
| KEGG = D06283
| C=21|H=19|N=2|Na=1|O=5
| molecular_weight = 402.4 g/mol
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category = —
| legal_status = Investigational
| routes_of_administration = [[Intravenous|IV]]
| smiles = CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)[O-])C(=O)C(=O)N.[Na+]
| StdInChI = 1S/C21H20N2O5.Na/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13;/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25);/q;+1/p-1
| StdInChIKey = XZZUHXILQXLTGV-UHFFFAOYSA-M
}}

'''Varespladib sodium''' (also known as '''A-001''', previously LY315920 and S-5920) is a sodium salt of varespladib designed for [[intravenous]] delivery.<ref name="vs">{{cite web|title=A-001: Prevention of Acute Chest Syndrome in Sickle Cell Disease.|publisher=Anthera Pharmaceuticals.|accessdate=18 August 2011|url=http://www.anthera.com/products_a001.asp
}}</ref> It was under evaluation by Anthera Pharmaceuticals as an anti-inflammatory [[phospholipase A2#Secreted phospholipases A2 (sPLA2)|sPLA2]] inhibitor for the prevention of [[acute chest syndrome]] (ACS), the leading cause of death for patients with [[sickle-cell disease]].<ref name="pr"/>

Elevated [[blood serum|serum]] levels of sPLA2 have been observed in sickle-cell patients preceding and during ACS episodes. This profound elevation in sPLA2 levels is not observed in sickle-cell patients at steady-state or during a [[vaso-occlusive crisis]], or in patients with [[respiratory diseases]] such as [[pneumonia]].<ref>{{cite journal|vauthors=Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA |title=Phospholipase A2 levels in acute chest syndrome of sickle cell disease.|journal=Blood|date=March 1996|volume=87|issue=6|pages=2573–78|pmid= 8630425| url=http://bloodjournal.hematologylibrary.org/content/87/6/2573.full.pdf
}}</ref><ref>{{cite journal|vauthors=Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA |title=Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease|journal=Blood|date=November 2000|volume=96|issue=9|pages=3276–78| pmid=11050014 |url=http://bloodjournal.hematologylibrary.org/content/96/9/3276.full
}}</ref> A reduction in serum sPLA2 levels, for example through [[blood transfusion]], reduces the risk of an ACS, suggesting that sPLA2 plays an important role in the onset of ACS.<ref>{{cite journal |vauthors=Bostrom M, Boyanovsky B, Jordan C, Wadsworth M, Taatjes D, de Beer F, etal |title=Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.|journal=Arteriosclerosis, Thrombosis, and Vascular Biology|date=March 2007|volume=27|issue=3|pages=600–06| pmid=17204667| doi=10.1161/01.ATV.0000257133.60884.44 |url=http://atvb.ahajournals.org/content/27/3/600.full
}}</ref>

Anthera Pharmaceuticals acquired varespladib sodium from [[Eli Lilly and Company|Lilly]] and [[Shionogi]] in 2006.<ref name="pr"/> In 2007, the U.S. [[Food and Drug Administration]] (FDA) granted varespladib sodium [[orphan drug]] status for its potential to treat patients with sickle-cell disease.<ref>{{cite press release|publisher=Anthera Pharmaceuticals, Inc.|title=Anthera's A-001 Receives Orphan Drug Status For The Prevention Of Acute Chest Syndrome In Patients With Sickle Cell Disease.|date=18 December 2007|url=http://investor.anthera.com/releasedetail.cfm?ReleaseID=423944
}}</ref> In 2009, Anthera Pharmaceuticals completed a [[Clinical trial#Phase II|Phase II]] study of varespladib sodium in subjects with sickle cell disease at risk for ACS.<ref>{{cite web|author=ClinicalTrials.gov.|title=IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome.|publisher=United States National Institute of Health.|accessdate=18 August 2011|url=http://clinicaltrials.gov/ct2/show/NCT00434473
}}</ref>

==References==
{{reflist}}

==External links==
* [http://www.anthera.com/products_a002.asp Varespladib methyl at Anthera.com]
* [http://www.anthera.com/products_a001.asp Varespladib sodium at Anthera.com]
* [http://clinicaltrials.gov/ct2/show/NCT01130246 Varespladib methyl Phase III study at ClinicalTrials.gov]
* [http://clinicaltrials.gov/ct2/show/NCT00434473 Varespladib sodium Phase II study at ClinicalTrials.gov]

{{Anti-inflammatory and antirheumatic products}}

[[Category:Indoles]]
[[Category:Carboxamides]]
[[Category:Carboxylic acids]]


{{cardiovascular-drug-stub}}
{{respiratory-system-drug-stub}}